March 14, 2023 Greg Aftayev
Carl Icahn takes aim at genome sequencer Illumina over Grail deal
Read M&A insights you won’t find elsewhere
- Exclusive scoops
- Smart data to help spot risk and opportunity
- Analysis of broader trends in M&A
- Lex, our agenda-setting business commentary (Premium only)
- Due Diligence, an exclusive M&A newsletter (Premium only)
Subscribe to unlock this article
Try unlimited access
Try full digital access and see why over 1 million readers subscribe to the FT
Only$1 for 4 weeks
- Then $69 per month
- New customers only
- Cancel anytime during your trial
Purchase a Trial subscription for $1 for 4 weeks You will be billed $69 per month after the trial ends
Explore our subscriptions
Find the plan that suits you best.
Premium access for businesses and educational institutions.
Check if youruniversity ororganisation offers FT membership to read for free.